Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 125 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Myocardial Infarction With ST Elevation Clear all
Completed Phase 1Phase 2 Interventional

Safety of TG100-115 for Heart Attack Treated With Angioplasty

NCT00103350
View directory record Official record
Conditions
Myocardial Infarction
Interventions
TG100-115
Drug
Lead sponsor
TargeGen
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Jun 26, 2026, 5:39 PM EDT
Completed No phase listed Observational Results available

National Cardiogenic Shock Initiative

NCT03677180
View directory record Official record
Conditions
Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI, Heart Attack
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
75
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jun 26, 2026, 5:39 PM EDT
Completed No phase listed Observational

Monocytosis and Culprit Vessel in STEMI Patients

NCT01569646
View directory record Official record
Conditions
STEMI
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

NCT01076764
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
13,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI

NCT00093184
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Blue Island, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2006 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms

NCT04231097
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina, STEMI, NSTEMI - Non-ST Segment Elevation MI
Interventions
MBCT intervention for ACS patients
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Jun 26, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional

Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients

NCT01655433
View directory record Official record
Conditions
ST-elevation MI, Hypothermia
Interventions
Velomedix APLS device, No Hypothermia Treatment
Device · Other
Lead sponsor
Velomedix, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Huntsville, Alabama • Los Angeles, California • Gainesville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mg, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Jun 26, 2026, 5:39 PM EDT
Not listed No phase listed Observational

Finding Acute Coronary Syndromes (ACS) With Serial Troponin Testing for Rapid Assessment of Cardiac Ischemic Symptoms

NCT00880802
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Not listed
Lead sponsor
Nanosphere, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Davis, California • San Diego, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

NCT03048825
View directory record Official record
Conditions
ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
Interventions
Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo
Drug · Device
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
7,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack

NCT00093197
View directory record Official record
Conditions
Myocardial Infarction
Interventions
KAI-9803 for Injection, Placebo
Drug
Lead sponsor
KAI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

NCT00271765
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
INO-1001
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
10
States / cities
Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Jun 26, 2026, 5:39 PM EDT
Not listed Not applicable Interventional

Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery & Risk Area in Patients w/ NSTEMI.

NCT02014701
View directory record Official record
Conditions
STEMI
Interventions
Echocardiogram
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
31 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

NCT01324453
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Post Conditioning + Primary PCI, Standard Primary PCI
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

NCT03507777
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Stenosis, Atherosclerosis, STEMI, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Interventions
Coronary PCI guided by OCT, Coronary PCI guided by Angiography
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Burlingame, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Jun 26, 2026, 5:39 PM EDT
Active, not recruiting Not applicable Interventional

Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

NCT03947619
View directory record Official record
Conditions
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Interventions
Impella CP® placement prior to reperfusion with Primary PCI
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 26, 2026, 5:39 PM EDT
Completed No phase listed Observational

Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes

NCT06851325
View directory record Official record
Conditions
STEMI, Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years to 79 Years
Enrollment
6,180 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jun 26, 2026, 5:39 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluation of CCR2 in Patients Post Myocardial Infarction

NCT05107596
View directory record Official record
Conditions
Heart Diseases
Interventions
64Cu-DOTA-ECL1i
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jun 26, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

NCT05305911
View directory record Official record
Conditions
Heart Attack, Enlarged Heart
Interventions
SGLT-2 inhibitors, Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

NCT01495364
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction
Interventions
NBS10, placebo
Biological · Other
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
58
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)

NCT00077792
View directory record Official record
Conditions
Myocardial Infarction, Acute ST-Segment Elevation
Interventions
Enoxaparin sodium (XRP4563)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
20,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2009 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

NCT00699998
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Clopidogrel, Prasugrel, Commercially-available Aspirin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
9,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
165
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

NCT01863134
View directory record Official record
Conditions
Non ST Elevation Myocardial Infarction
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
Medical University of Silesia
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Jun 26, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

NCT00043784
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Myocardial Ischemia
Interventions
enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Jun 26, 2026, 5:39 PM EDT